Optimization of an animal model of experimental autoimmune encephalomyelitis achieved with a multiple MOG35-55 peptide in C57BL6/J strain of mice

Journal of Autoimmunity

Volumn 20, Issue 1, 2003, Pages 51-61

  Costa, Odile ^a,b   Divoux, Didier ^c   Ischenko, Alexander ^d   Tron, François ^a   Fontaine, Marc ^a  

^a INSERM   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c GIP CYCERON   (France)

^d Institute for Highly Pure Biopreparations   (Russian Federation)

Author keywords

Autoimmunity; Experimental autoimmune encephalomyelitis multiple sclerosis; Multiple antigen peptide; Myelin oligodendrocyte glycoprotein; Neuroimmunology

Indexed keywords

FREUND ADJUVANT; GLIAL FIBRILLARY ACIDIC PROTEIN; LYSINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN[35-55]; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; ASTROCYTE; AUTOIMMUNE DISEASE; BIOSYNTHESIS; BLOOD VESSEL; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE COURSE; DISEASE SEVERITY; ENCEPHALOMYELITIS; FEMALE; GENETIC HETEROGENEITY; IMMUNIZATION; LATERAL BRAIN VENTRICLE; LEUKOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; MOUSE STRAIN; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL CORD;

EID: 0037322194     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-8411(02)00108-7     Document Type: Article

References (62)

1. Pettinelli C.B., Fritz R.B., Chou C.H., McFarlin D.E. Encephalitogenic activity of guinea pig myelin basic protein in the SJL mouse. J Immunol. 129:1982;1209-1211.
2. Chou C.H., Shapira R., Fritz R.B. Encephalitogenic activity ofthe small form of mouse myelin basic protein in the SJL/J mouse. J Immunol. 130:1983;2183-2186.
3. Williams R.M., Lees M.B., Cambi F., Macklin W.B. Chronic experimental allergic encephalomyelitis induced in rabbits with bovine white matter proteolipid apoprotein. J Neuropathol Exp Neurol. 41:1982;508-521.
4. Tuohy V.K., Sobel R.A., Lees M.B. Myelin proteolipid protein-induced experimental allergic encephalomyelitis. Variations of disease expression in different strains of mice. J Immunol. 140:1988;1868-1873.
5. Adelmann M., Wood J., Benzel I., Fiori P., Lassmann H., Matthieu J.M., et al. The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. J Neuroimmunol. 63:1995;17-27.
6. Amor S., Groome N., Linington C., Morris M.M., Dornmair K., Gardinier M.V., et al. Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice. J Immunol. 153:1994;4349-4356.
7. Johns T.G., Kerlero de Rosbo N., Menon K.K., Abo S., Gonzales M.F., Bernard C.C. Myelin oligodendrocyte glycoprotein inducesa demyelinating encephalomyelitis resembling multiple sclerosis. J Immunol. 154:1995;5536-5541.
8. Kerlero de Rosbo N., Mendel I., Ben-Nun A. Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: preliminary analysis of MOG T-cell epitopes. Eur J Immunol. 25:1995;985-993.
9. Slavin A., Ewing C., Liu J., Ichikawa M., Slavin J., Bernard C.C. Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein. Autoimmunity. 28:1998;109-120.
10. Lassmann H., Brunner C., Bradl M., Linington C. Experimental allergic encephalomyelitis: the balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyelinated lesions. Acta Neuropathol (Berl). 75:1988;566-576.
11. Linington C., Bradl M., Lassmann H., Brunner C., Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed againsta myelin-oligodendrocyte glycoprotein. Am J Pathol. 130:1988;443-454.
12. Xiao B.G., Linington C., Link H. Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls. J Neuroimmunol. 31:1991;91-96.
13. Piddlesden S.J., Lassmann H., Zimprich F., Morgan B.P., Linington C. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol. 143:1993;555-564.
14. Reindl M., Linington C., Brehm U., Egg R., Dilitz E., Deisenhammer F., et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain. 122:1999;2047-2056.
15. Fritz R.B., Skeen M.J., Chou C.H., Garcia M., Egorov I.K. Major histocompatibility complex-linked control of the murine immune response to myelin basic protein. J Immunol. 134:1985;2328-2332.
16. McDonnell G.V., Hawkins S.A. Primary progressive multiplesclerosis: a distinct syndrome? Mult Scler. 2:1996;137-141.
17. Confavreux C., Vukusic S., Moreau T., Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 343:2000;1430-1438.
18. 't Hart B.A., van Meurs M., Brok H.P., Massacesi L., Bauer J., Boon L., et al. A new primate model for multiple sclerosis in the common marmoset. Immunol Today. 21:2000;290-297.
19. 24-36is presented by a monomorphic MHC class II molecule. J Immunol. 165:2000;1093-1101.
20. Yamada M., Kagawa T., Ikenaka K. Development and differentiation of oligodendrocytes. Jpn J Physiol. 46:1996;105-110.
21. bmice: finespecificity and T-cell receptor V beta expression of encephalitogenic T cells. Eur J Immunol. 25:1995;1951-1959.
22. bmice. Eur J Immunol. 26:1996;2470-2479.
23. Heeger P.S., Forsthuber T., Shive C., Biekert E., Genain C., Hofstetter H.H., et al. Revisiting tolerance induced by autoantigen in incomplete Freund's adjuvant. J Immunol. 164:2000;5771-5781.
24. Smith M.E., Somera F.P., Eng L.F. Immunocytochemical staining for glial fibrillary acidic protein and the metabolism of cytoskeletal proteins in experimental allergic encephalomyelitis. Brain Res. 264:1983;241-253.
25. Webster H.D., Shii H., Lassmann H. Immunocytochemical study of myelin-associated glycoprotein (MAG), basic protein (BP) and glial fibrillary acidic protein (GFAP) in chronic relapsing experimental allergic encephalomyelitis (EAE). Acta Neuropathol (Berl). 65:1985;177-189.
26. Smith M.E., Eng L.F. Glial fibrillary acidic protein in chronicrelapsing experimental allergic encephalomyelitis in SJL/J mice. J Neurosci Res. 18:1987;203-208.
27. Kothavale A., Di Gregorio D., Somera F.P., Smith M.E. GFAP mRNA fluctuates in synchrony with chronic relapsing EAE symptoms in SJL/J mice. Glia. 14:1995;216-224.
28. Eng L.F., D'Amelio F.E., Smith M.E. Dissociation of GFAP intermediate filaments in EAE: observations in the lumbar spinal cord. Glia. 2:1989;308-317.
29. r) mice. Eur J Immunol. 21:1991;693-699.
30. Blankenhorn E.P., Butterfield R.J., Rigby R., Cort L., Giambrone D., McDermott P., et al. Genetic analysis of the influence of pertussis toxin on experimental allergic encephalomyelitis susceptibility: an environmental agent can override genetic checkpoints. J Immunol. 164:2000;3420-3425.
31. Abdul-Majid K.B., Jirholt J., Stadelmann C., Stefferl A., Kjellen P., Wallstrom E., et al. Screening of several H-2 congenic mouse strains identified H-2(q) mice as highly susceptible to MOG-induced EAE with minimal adjuvant requirement. J Neuroimmunol. 111:2000;23-33.
32. Posnett D.N., McGrath H., Tam J. A novel method for producing anti-peptide antibodies. Production of site-specific antibodies to the T-cell-antigen receptor beta-chain. J Biol Chem. 263:1988;1719-1725.
33. Fernando G.J., Stenzel D.J., Tindle R.W., Merza M.S., Morein B., Frazer I.H. Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production. Vaccine. 13:1995;1460-1467.
34. Tam J.P., Spetzler J.C. Chemoselective approaches to the preparation of peptide dendrimers and branched artificial proteins using unprotected peptides as building blocks. Biomed Proteins Nucleic Acids. 1:1995;123-132.
35. Tam J.P. Recent advances in multiple antigen peptides. J Immunol Methods. 196:1996;17-32.
36. Fitzmaurice C.J., Brown L.E., McInerney T.L., Jackson D.C. The assembly and immunological properties of non-linear synthetic immunogens containing T-cell and B-cell determinants. Vaccine. 14:1996;553-560.
37. Fitzmaurice C.J., Brown L.E., Kronin V., Jackson D.C. The geometry of synthetic peptide-based immunogens affects the efficiency of T-cell stimulation by professional antigen-presenting cells. Int Immunol. 12:2000;527-535.
38. Falk K., Rötzschke O., Santambrogio L., Dorf M.E., Brosnan C., Strominger J.L. Induction and suppression of an autoimmune disease by oligomerized T-cell epitopes: enhanced in vivo potency of encephalitogenic peptides. J Exp Med. 191:2000;717-730.
39. Arnason B.G.W., Reder A.T. Interferons and multiple sclerosis. Clin Neuropharmacol. 17:1994;495-547.
40. Ben-Nun A., Lando Z. Detection of autoimmune cells proliferating to myelin basic protein and selection of T cell lines that mediate experimental autoimmune encephalomyelitis (EAE) in mice. J Immunol. 130:1983;1205-1209.
41. Baron J.L., Madri J.A., Ruddle N.H., Hashim G., Janeway C.A. Jr. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med. 177:1993;57-68.
42. Kuchroo V.K., Sobel R.A., Yamamura T., Greenfield E., Dorf M.E., Lees M.B. Induction of experimental allergic encephalomyelitis by myelin proteolipid-protein-specific T-cell clones and synthetic peptides. Pathobiology. 59:1991;305-312.
43. Linington C., Berger T., Perry I., Weerth S., Hinze-Selch D., Zhang Y., et al. T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur J Immunol. 23:1993;1364-1372.
44. 2developmental pathways: application to autoimmune disease therapy. Cell. 80:1995;707-718.
45. Sela M. Specific vaccines against autoimmune diseases. CR Acad Sci Sér III. 322:1999;933-938.
46. 2immune regulation induced by T-cell vaccination in patients with multiple sclerosis. Eur J Immunol. 30:2000;908-913.
47. Schijns V.E. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol. 12:2000;456-463.
48. Rook G.A., Ristori G., Salvetti M., Giavannoni G., Thompson E.J., Stanford J.L. Bacterial vaccines for the treatment of multiple sclerosis and other autoimmune disorders. Immunol Today. 21:2000;503-508.
49. Rabchevsky A.G., Degos J.D., Dreyfus P.A. Peripheral injections of Freund's adjuvant in mice provoke leakage of serum proteins through the blood-brain barrier without inducing reactive gliosis. Brain Res. 832:1999;84-96.
50. Miller A., Lider O., Weiner H.L. Antigen-driven bystander suppression after oral administration of antigens. J Exp Med. 174:1991;791-798.
51. Lipkowski A.W., Baranowska B., Marczak E., Kwiatkowska-Patzer B., Gajkowska B., Walski V. Protein hydrolysates for oral tolerance. Biofactors. 12:2000;147-150.
52. Stienekemeier M., Falk K., Rötzschke O., Weishaupt A., Schneider C., Toyka K.V., et al. Vaccination, prevention, and treatment of experimental autoimmune neuritis (EAN) by an oligomerized T-cell epitope. Proc Natl Acad Sci USA. 98:2001;13872-13877.
53. Suko M., Ogita T., Okudaira H., Horiuchi Y. Preferential enhancement of IgE antibody formation by Bordetella pertussis. Int Arch Allergy Appl Immunol. 54:1977;329-337.
54. Bernard C.C., Johns T.G., Slavin A., Ichikawa M., Ewing C., Liu J., et al. Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J Mol Med. 75:1997;77-88.
55. Kerlero de Rosbo N., Hoffman M., Mendel I., Yust I., Kaye J., Bakimer R., et al. Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. Eur J Immunol. 27:1997;3059-3069.
56. Kerlero de Rosbo N., Brok H.P., Bauer J., Kaye J.F., 't Hart B.A., Ben-Nun A. Rhesus monkeys are highly susceptible to experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein: characterisation of immunodominantT- and B-cell epitopes. J Neuroimmunol. 110:2000;83-96.
57. Encinas J.A., Weiner H.L., Kuchroo V.K. Inheritance of susceptibility to experimental autoimmune encephalomyelitis. J Neurosci Res. 45:1996;655-669.
58. Encinas J.A., Lees M.B., Sobel R.A., Symonowicz C., Weiner H.L., Seidman C.E., et al. Identification of genetic loci associated with paralysis, inflammation and weight loss in mouse experimental autoimmune encephalomyelitis. Int Immunol. 13:2001;257-264.
59. Butterfield R.J., Blankenhorn E.P., Roper R.J., Zachary J.F., Doerge R.W., Teuscher C. Identification of genetic loci controlling the characteristics and severity of brain and spinal cord lesionsin experimental allergic encephalomyelitis. Am J Pathol. 157:2000;637-645.
60. Olsson T., Dahlman I., Wallstrom E., Weissert R., Piehl F. Genetics of rat neuroinflammation. J Neuroimmunol. 107:2000;191-200.
61. Dahlman I., Wallstrom E., Weissert R., Storch M., Kornek B., Jacobsson L., et al. Linkage analysis of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in the rat identifies a locus controlling demyelination on chromosome 18. Hum Mol Genet. 8:1999;2183-2190.
62. Maron R., Hancock W.W., Slavin A., Hattori M., Kuchroo V., Weiner H.L. Genetic susceptibility or resistance to autoimmune encephalomyelitis in MHC congenic mice is associated with differential production of pro- and anti-inflammatory cytokines. Int Immunol. 11:1999;1573-1580.